PT-141 (Bremelanotide) — cyclic heptapeptide melanocortin receptor agonist. Studied for MC3R and MC4R signaling pathways and CNS receptor research in preclinical models. 10mg lyophilized, HPLC + mass spec verified.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and melanocortin receptor agonist derived from Melanotan II. Unlike Melanotan II, PT-141 is a cyclic structure that acts specifically on melanocortin receptor subtypes MC3R and MC4R — receptors expressed in the central nervous system — rather than the peripheral MC1R melanocyte receptor.
In preclinical research, PT-141 is investigated for its melanocortin receptor signaling properties, CNS pathway activation, and the downstream effects of MC3R/MC4R agonism on energy balance and neural signaling. It has also undergone clinical investigation — making it one of the few research peptides with FDA-approved drug status (Vyleesi).
For a full breakdown of the research literature, read our PT-141 research guide →
CoreVionRX doesn’t manufacture peptides. What we do — rigorously — is verify every batch before it reaches our catalog.
Everything you need to evaluate this compound for your research protocol.
| Specification | Value |
|---|---|
| Compound | PT-141 (Bremelanotide) |
| Structure | Cyclic heptapeptide melanocortin agonist |
| Receptor Targets | MC3R, MC4R (central melanocortin receptors) |
| Origin | Derivative of Melanotan II — cyclic analog |
| Form | Lyophilized powder |
| Vial Size | 10mg per vial |
| Purity | ≥98% by reversed-phase HPLC |
| Identity | Confirmed by electrospray ionization mass spectrometry |
| Storage (lyophilized) | −20°C, protected from light and moisture. Stable 24+ months. |
| Storage (reconstituted) | 2–8°C, away from light |
| Reconstitution | Bacteriostatic water |
| Documentation | Lot-specific COA with HPLC chromatogram — included with every order |
All published research is preclinical — cell cultures and animal models. No human clinical trial data exists for PT-141. Here’s where the science currently stands.
Wessells H. et al. (2003) J Urol 170(1):116-9
Diamond LE. et al. (2004) J Urol 172(5 Pt 1):1999-2004
Cone RD. (2006) Nat Neurosci 9(8):1019-23
Most peptide vendors claim purity. We document it. Every compound ships with independent lab verification — not because regulations require it, but because you deserve to know exactly what you’re working with.
In stock. COA included. HPLC + mass spec verified. Ships with full documentation.
For laboratory research use only. Not for human or animal consumption.
CoreVionRX supplies research compounds to qualified laboratories and research institutions.
Documentation & Testing Standards
Every batch is independently tested before release. Research peptide FAQs · CoreVionRX testing standards
Related Research Compounds